Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor
Open Access
- 15 February 2008
- journal article
- research article
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 6 (1) , 7
Abstract
Background: Asthma is a complex disease, characterized by reversible airway obstruction, hyperresponsiveness and chronic inflammation. Principle pharmacologic treatments for asthma include bronchodilating beta2-agonists and anti-inflammatory glucocorticosteroids; but these agents do not target the main cause of the disease, the generation of pathogenic Th2 cells. We previously reported reduction in allergic inflammation in mice deficient in the ANP receptor NPRA. Here we determined whether siRNA for natriuretic peptide receptor A (siNPRA) protected against asthma when administered transdermally. Methods: Imiquimod cream mixed with chitosan nanoparticles containing either siRNA green indicator (siGLO) or siNPRA was applied to the skin of mice. Delivery of siGLO was confirmed by fluorescence microscopy. The anti-inflammatory activity of transdermal siNPRA was tested in OVA-sensitized mice by measuring airway hyperresponsiveness, eosinophilia, lung histopathology and pro-inflammatory cytokines. Results: SiGLO appearing in the lung proved the feasibility of transdermal delivery. In a mouse asthma model, BALB/c mice treated with imiquimod cream containing siNPRA chitosan nanoparticles showed significantly reduced airway hyperresponsiveness, eosinophilia, lung histopathology and pro-inflammatory cytokines IL-4 and IL-5 in lung homogenates compared to controls. Conclusion: These results demonstrate that topical cream containing imiquimod and siNPRA nanoparticles exerts an anti-inflammatory effect and may provide a new and simple therapy for asthma.Keywords
This publication has 27 references indexed in Scilit:
- Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophyllineRespiratory Research, 2006
- Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 geneNature Medicine, 2004
- Effect of Chitosan on Epithelial Cell Tight JunctionsPharmaceutical Research, 2004
- Transfection of mEpo gene to intestinal epitheliumin vivomediated by oral delivery of chitosan-DNA nanoparticlesWorld Journal of Gastroenterology, 2004
- Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix)Journal of Pharmacy and Pharmacology, 2002
- Efficacy of a novel chitosan formulation on fecal fat excretion: a double-blind, crossover, placebo-controlled study.2002
- Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiencyJournal of Controlled Release, 2001
- Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome–plasmid DNA complexesInternational Journal of Pharmaceutics, 2000
- Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergyNature Medicine, 1999
- Characterization of binding and TNF-α-inducing ability of chitosans on monocytes: the involvement of CD14Vaccine, 1994